Scholars Central

Conference abstractPublished 11 May 2023

Multitarget inhibitors as anticancer agents with oncoinmunomodulatory properties

Authors: Raquel Gil-Edo

Jaume I University, Spain

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Solid tumours are no longer understand as isolated masses of mutant cells, more and more recent studies show that, it is compound by a dynamic network of tumour and stromal cells, and macromolecules, that all together forms the tumour microenvironment (TME).1 In last few years, the role of immune system in tumour evolution after the infiltration of immune cells, such as Dendritic Cells (DC), Natural Killer cells (NK), macrophages or T cell among others, in TME has been largely studied. Thereby, Programmed Death Ligand-1 (PD-L1) has become an interesting target in the study of new anticancer treatments as their implication as immune inhibitor checkpoint.2 Moreover, it is been demonstrated that immune system also drives to the progression of angiogenesis by overproducing Vascular Endothelial Growth Factor (VEGF), and, furthermore, VEGF by binding its receptor, Vascular Endothelial Growth Factor Receptor-2 (VEGFR2), it is able to inhibit the activation of T cells by mature DC.3 This makes it especially interesting to find a multitarget agent capable to inhibit not only PD-L1 protein but also VEGFR2 receptor. Previous studies developed in our group revealed Aryl Urea4, 5 and Aryl Triazole6, 7 as good scaffolds for designing multitarget oncoimmunomodulator agents. Recently, we developed some derivatives constituted by diaryl urea moiety connected to another aromatic group by a flexible chain as new multitarget inhibitors and here, we are presenting the results we obtained in preliminary biological studies proving the ability of some compounds, that have been designed and synthetised, in modulating the immune system.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cancer Research and Immuno-Oncology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer Research and Immuno-Oncology
  • SubjectOncology & Cancer
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Raquel Gil-Edo”